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The COVID-19 pandemic has been occurring approximately for more than 1 year. This pandemic
has been a health issue that hits all countries in the world caused by the transmission of SARSCoV-2 virus from one individual to another. The symptoms showed from the infected are fever,
shortness of breath, dry cough, headache, and sore throat, among others. The SARS-CoV-2 virus
is transmitted through sneezing, coughing, talking, and touching infected objects. Along with this
transmission, the SARS-CoV-2 virus will continue to mutate. This mutation becomes an obstacle
as well as a challenge to find drugs that can overcome the SARS-CoV-2 virus effectively and safely.
The drugs used as anti-COVID-19 are still limited. The steps taken in the process of discovering
and developing anti-COVID-19 drugs were through the drug repurposing approach because
of the advantages it provides, such as shortens the duration and minimizes the costs required.
After several drugs that have potential as anti-COVID-19 were obtained, further research on the
development of dosage forms and formulas was carried out to obtain more effective and safer antiCOVID-19 drugs. This review aims to discuss several drugs gained from drug repurposing that
have the potential as anti-COVID-19 drugs such as remdesivir, chloroquine/hydroxychloroquine,
azithromycin, corticosteroids, and other potential drugs. This review will also discuss several
developments of dosage form from the repurposed drugs.
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INTRODUCTION
The COVID-19 pandemic is a current global health
issue with rapid transmission between individuals by
the SARS-CoV-2 virus. This virus is a new type of
betacoronavirus from the coronaviridae family and is
responsible for infectious diseases of the respiratory
tract, gastrointestinal tract, liver, and nervous system in
mammals, besides alphacoronavirus (Sheikhzadeh et al.,
2020; Ye et al., 2020). The name of this virus is derived
from Latin word “corona” which means ‘crown’ because
this virus has a crown-like shape which is formed from
the spike protein on the surface of its cell when viewed
with a microscope (Sharma et al., 2020). Two thirds of
the genomic structure of the SARS-CoV-2 virus is RNA
polymerase which has a function to encode the synthesis
of RNA and large polyproteins that are not involved
in modulating the host response, while another third
is genes that encode the 4 types of structural proteins
such as spike (S), envelope (E), membrane (M), and
nucleocapsid (N) (Sheikhzadeh et al., 2020). In addition,
the SARS-CoV-2 virus has a nucleotide with 78%
similarity to the SARS virus and 50% to the MERS virus,
but SARS-CoV-2 has faster transmission rate than those
two viruses (Sheikhzadeh et al., 2020; Yang et al., 2020).
The SARS-CoV-2 virus can be transmitted from one
individual to another directly or indirectly. The direct

transmission of the SARS-CoV-2 virus is through
droplets of body fluids from the respiratory tract when
an infected person coughs, sneezes, or talks. On the other
hand, the transmission of this virus indirectly occurs
when a person touches other individuals or objects that
have been contaminated and subsequently touches own
mucous membranes such as eyes, mouth, or nose (Lotfi
et al., 2020; Sharma et al., 2020). After being infected
with the virus, the patient will show common symptoms
such as fever, dry cough, shortness of breath, sore throat,
headache, nasal congestion, sneezing, fatigue, and
muscle aches (Hui et al., 2020; Lotfi et al., 2020; Sharma
et al., 2020). The worst repercussion of the infection
is death. The reason of these mortalities is suspected
to be a condition called “cytokine storm” or “cytokine
storm syndrome (CSS)” or “cytokine release syndrome
(CRS)” (Behrens & Koretzky, 2017). Cytokine storm
is a condition in which innate and adaptive immune
response, such as tumor necrosis factor-α (TNF-α),
interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, interferon-γ,
granulocyte colony-stimulating factor, and many other
cytokines are uncontrollable which can lead to apoptosis
of epithelial cells and endothelial cells, vascular leakage
and even death (Channappanavar & Perlman, 2017; Lee
et al., 2015). Many studies also showed that on severe
conditions of COVID-19, it tended to have higher
concentration of cytokine, especially IL-6, compared
to moderate conditions (Chen et al., 2020; Ramanathan
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et al., 2020). Furthermore, through postmortem
examination of the lung organ from COVID-19 patient,
sign of acute respiratory distress syndrome (ARDS)
and lymphocyte T-cells overactivation was shown. This
condition can lead to high and uncontrollable cytotoxity
of the T-cells against its host (Tang et al., 2020; Xu Z,
Shi L, Wang Y, 2020).
SARS-CoV-2 virus is very small in size, which ranges
from 60 to 100 nm, it has round or slightly oval shape,
and sheathed. It also has a single-chain RNA with 29.9
kb, and can live in conditions of 5 to 11 ̊C and 47 to 79%
humidity ratio. However, this virus can be inactivated
by using UV light or heating to 56 ̊C for 30 minutes and
is also sensitive to disinfectants such as 75% ethanol
(Lotfi et al., 2020; Zhu et al., 2020). In addition, the
SARS-CoV-2 virus also has a high rate of mutation
and recombinant, allowing the virus to mutate rapidly
after being transmitted from one individual to another
(Sheikhzadeh et al., 2020). This condition becomes
an obstacle as well as a challenge for researchers to
discover and develop specific drugs or vaccines for
SARS-CoV-2 virus. Until now, several steps have been
taken by the researchers including drug repurposing, and
after some drugs are discovered to have potential as antiCOVID-19, those candidates were developed into more
effective and safer pharmaceutical dosage forms than the
marketed products.
DRUG REPURPOSING
The process of discovering and developing new drugs
until being approved by the drug regulatory agencies
such as the Food and Drug Administration (FDA) may
take a long time, around 10 to 15 years, and requires a lot
of expenses (Parvathaneni et al., 2019). Especially in the
current COVID-19 pandemic, classical drug discovery
approaches are not preferable since there is an urgent
need of drugs and vaccines that are effective for SARSCoV-2 virus. Therefore, researchers began to shift from
classical approaches to drug repurposing approaches as
an alternative to drug discovery and development.
Drug repurposing, also known as drug repositioning,
drug reprofiling or drug re-tasking, is a strategy for
discovering, researching and developing new therapeutic
indications for drugs besides the indication that has been
approved by the drug regulatory agencies. The advantage
of the drug repurposing approach is that it shortens the
duration of drug discovery and development process
because the safety profile of the drug which being
studied was known so that the phase 1 in clinical trials
can be skipped. In addition, drug repurposing can also
reduce the costs required in its process and has lesser
risk in the research (Agrawal, 2015; Parvathaneni et al.,
2019; Zhou et al., 2020).
E-ISSN 2477-0612
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The ideal anti-COVID-19 drug strategy is through
3 mechanisms. First, by targeting the Angiotensin
Converting Enzyme 2 (ACE-2) receptor, which is the
receptor used by the SARS-CoV-2 virus to infect the
host. When the drug binds to the ACE-2 receptor, the
SARS-CoV-2 virus will not be able to bind to the ACE2 receptor and infection can be avoided. The second
mechanism is by targeting the Receptor Binding Domain
(RBD) on the spike protein of SARS-CoV-2 virus, thus
when the drug binds to the RBD of the SARS-CoV-2
virus, the virus cannot bind to the ACE-2 receptor and the
infection will also be avoided. The third mechanism is by
targeting the main protease (Mpro) enzyme, which plays
an important role in viral transcription and replication.
When the drug is designed to inhibit the Mpro enzyme,
the drug will prevent the process of viral transcription
and replication and eventually kill the virus (Zhu et al.,
2020). Until now, many drugs have been studied for antiCOVID-19 activity. Here are some examples of drugs
that have been studied and show potential activities as
anti-COVID-19.
Remdesivir
Remdesivir is an adenosine nitrogen base analogue
compound that forms nucleosides. Initially, remdesivir
or GS-5734 was used as an antiviral drug for ebola virus
which attacked West Africa. Remdesivir also turned
out to be a prodrug, therefore when remdesivir is used,
it will undergo a metabolism process and becomes
its active metabolite called GS-441524 which has a
role as a competitive inhibitor to the dependent RNA
enzyme - RNA polymerase (RdRp) so that the synthesis
and replication of viral RNA process can be inhibited
(Frediansyah et al., 2020; Warren et al., 2016). In an invitro test of the anti-COVID-19 activity from remdesivir,
satisfying results were obtained, where remdesivir
effectively inhibits SARS-CoV-2 infection on Vero E6
cells by 90% at concentrations of 1.76 μM (Wang et al.,
2020).
Trial on remdesivir as an anti-COVID-19 drug has
also gone through the preclinical testing phase. In one
study, remdesivir was administered at a dose of 10 mg/
kg BW intravenously to rhesus macaques that had been
infected with the SARS-CoV-2 virus. After 12 hours,
remdesivir was given orally at a dose of 5 mg / kgBW for
7 days. Subsequently, the level of damage of lung organ
histopathologically and the number of infectious viruses
after treatment were evaluated. The results obtained
showed that the remdesivir-treated group did not show
any sign of lung damage and the number of virus titre in
bronchoalveolar lavage was also found to decrease about
100 fold lower than the controls group after 12 hours and
no longer detected after 3 days (Williamson et al., 2020).
Clinical trial of remdesivir has also been carried out on
53 COVID-19 patients from January to March 2020 in
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a hospital in New England. The patients were given 200
mg of remdesivir intravenously on the first day, followed
by 100 mg daily for 9 days. The results showed that 36
out of 53 patients (about 68%) had improvement of
clinical quality of life (Grein et al., 2020).

can be avoided (Pani et al., 2020; Rizk et al., 2020;
Zarogoulidis et al., 2012). Other studies showed that
azithromycin also has antiviral activity against zika
virus and rhinovirus through the induction of interferons
production (Retallack et al., 2016; Schögler et al., 2015).

Chloroquine / Hydroxychloroquine
Chloroquine is a derivate from quinoline compound that
has a chlorine group at position 7 and a 4-diethylamino1-methylbutylamino group at position 4 from quinoline
(White et al., 2020). Chloroquine and its analogue,
hydroxychloroquine, were originally developed in 1934
and were commonly used as antimalarial drugs and there
are also studies concluding that hydroxychloroquine can
be used for systemic lupus erythematosus treatment
(Giaime et al., 2020; Jallouli et al., 2015). Currently,
chloroquine and hydroxychloroquine have been studied
through drug repurposing and have been used as drugs
in the therapy of COVID-19 patients. Chloroquine
and hydroxychloroquine can act as antiviral agents
for COVID-19 by suppressing cytokine storms. The
mechanism occurs in 2 ways, the first is because
chloroquine and hydroxychloroquine are weak bases,
therefore can increase the pH of the endosome which
modulates toll-like receptor (TLR) signaling process
which leads to suppression of production of proinflammatory cytokines such as Tumor Necrosis Factor
(TNF), interleukin-6 (IL-6) and IL-1, while the second
route is through an increase in lysosome pH which
results in reduced T cell production so that cytokine
storms can be avoided (Tripathy et al., 2020).

The investigation of azithromycin activity as an antiCOVID-19 drug has been carried out on Vero E6 cells.
Results showed that azitrhomycin is one of the drugs that
has the potential to be anti-COVID-19 drug, with EC50
value of 2.12 μM (Touret et al., 2020). The ability of
azithromycin as an anti-COVID-19 drug combined with
hydroxychloroquine has been clinically tested. The study
was conducted by giving 600 mg hydroxychloroquine
and 500 mg azithromycin on the first day and 250 mg
once daily for 4 days. The results showed that when
hydroxychloroquine and azitrhomycin were combined,
effectivity can be increased compared to single
hydroxychloroquine therapy, where on the fifth day the
combination group showed negative results from PCR
test (Gautret et al., 2020). Another study recommends
to use an initial adult dose of 500 mg followed by 250
mg once daily for 4 days, and 10 mg/kg on the first day
followed by 5 mg/kg for 4 days after, for children under
18 years old (Schwartz & Suskind, 2020).

Results of an in-vitro study showed that
hydroxychloroquine has better potential than chloroquine
as an anti-COVID-19 drug, which were tested on Vero
E6 cells with an EC50 concentration of 0.72 μM for
hydroxychloroquine and 5.47 μM for chloroquine
(Yao et al., 2020). A clinical trial was conducted on
36 COVID-19 patients at The Mediterranee Infection
University Hospital Institute in Marseille, France by
administering hydroxychloroquine sulfate 200 mg 3
times daily for 10 days orally. The results obtained
showed that 70% of patients experienced virological
recovery (Gautret et al., 2020).
Azithromycin
Azithromycin is a macrolide antibiotic that has a
macrocyclic lactone ring. Initially azithromycin was
used as a bacteriostatic drug to Gram positive bacteria
which infects the respiratory tract (Giaime et al.,
2020; Pani et al., 2020). Interestingly, after several
studies, it was found that azithromycin can also act
as immunomodulator and regulates inflammatory
responses, increases immunoglobulin production and
suppresses the production of cytokines such as TNF-α,
IL-6, and IL-8, so that the cytokine storm reactions

Corticosteroid
Corticosteroids are steroid hormone compounds
that can be divided into mineralocorticoids and
glucocorticoids. Generally, the term corticosteroid refers
to the glucocorticoid group (Ramamoorthy et al., 2017).
Corticosteroid was originally used as an antiinflammatory
drug, although later shown to have an immuosupressive
effect as well. Because of that, corticosteroids could be
an alternative to reduce the infection of SARS-CoV-2
virus. The mechanism is through suppression of proinflammatory cytokine production (Ahmed & Hassan,
2020). One of the corticosteroids that is often used in
therapy is dexamethasone.
Clinical studies regarding the ability of dexamethasone
as anti-COVID-19 have been investigated. The study
was conducted by giving dexamethasone to infected
patients, either orally or intravenously (at random) at
a dose of 6 mg per day for 10 days. Afterwards, the
mortality rate after 28 days was evaluated. The results
obtained indicate that by using dexamethasone the
mortality rate can be reduced by 12.3% in patients using
invasive mechanical ventilation devices and 4.2% in
patients using oxygen alone (Horby et al., 2020).
Other Potential Drugs
Statins
Statins were originally used to inhibit sterol synthesis
pathway which can lead to lower concentration
E-ISSN 2477-0612
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Table 1. Repurposed drug as anti-covid-19 and their dosage forms development
Drug

Original Use

Remdesivir

Antiviral
Virus

for

Anti-COVID-19
Mechanism
Ebola Metabolized into its
active form called
“GS-441524”
and
subsequently inhibits
the dependent RNA
enzyme
RNA
polymerase
(RdRp)
competitively therefore
the synthesis and
replication of viral
RNA process can be
inhibited

Results

In-Vitro:
Dry Powder Inhalation:
Remdesivir effectively inhibits SARS- The dry powder was made by
CoV-2 infection on Vero E6 cells by 90% at thin film freezing method and
concentrations of 1.76 μM.
used leucine as the excipient and
acetonitrile:water (50:50) as the
In-Vivo:
solvent.
Remdesivir was administered at a dose of 10
mg/kg BW intravenously to infected rhesus The result from the evaluation of
macaques for the first 12 hours and orally at a the dry powder showed satisfying
dose of 5 mg / kgBW for 7 days. The results aerodynamic
characteristics
did not show any sign of lung damage and the as indicated by 89 – 92% of
number of virus titre in bronchoalveolar lavage the particle fractions that were
was 100 fold lower than the control group after successfully sprayed
12 hours and no longer detected after 3 days
Clinical Trial:
53 patients were given 200 mg of remdesivir
intravenously on the first day, followed by 100
mg daily for 9 days. The results showed that 36
out of 53 patients (about 68%) had improvement
of clinical quality of life. On the other hand, 32
of 36 subjects (60%) who received remdesivir
intravenously had at least one side effect and
12 subjects (23%) had a serious side effect. The
side effects that often occur are diarrhea, organ
dysfunction syndrome (septic shock), acute
kidney damage, and hypotension

E-ISSN 2477-0612

Development of Dosage Forms

References
Frediansyah et al.,
2020;
Grein et al., 2020;
Sahakijpijarn et al.,
2020;Wang et al.,
2020;
Warren et al., 2016;
Williamson et al.,
2020
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Table 1. continued
Drug

Original Use

C h l o r o q u i n e / Antimalaria
Hydroxychloroquine

Anti-COVID-19
Mechanism
The mechanism occurs
in 2 ways:
1. Chloroquine/ hydroxychloroquine
increase the pH
of the endosome
which modulates
TLR
signaling
process
which
leads to suppression of production
of pro-inflammatory
cytokines
such as TNF, IL-6
and IL-1
2. C h l o r o q u i n e /
h y d r o x y chloroquine
increases
the
lysosome
pH
which results in
reduced T cell
production so the
cytokine storms
can be avoided

Results

Development of Dosage Forms

References

In-Vitro:
Both hydroxychloroquine and chloroquine have
EC50 concentration of 0.72 μM and 5.47 μM,
respectively, which can inhibit SARS-CoV-2
infection on Vero E6 cells.

Liposomal hydrochloroquine:
The liposome was made with
DPPC and cholesterol. This
liposome is administered through
inhalation route. The result of preclinical trial on rats shows that
AUC and t1/2 were greater than
intravenous route, indicating that
the penetration ability is increased
with extended residence time. The
liposomal
hydroxychloroquine
also has higher maximum
concentration in lung than in
heart and blood plasma. It shows
that the delivery of liposomal
hydroxychloroquine via inhalation
route has a local effect in the lung
tissue.

Gautret et al., 2020;
Tai et al., 2020;
Tripathy et al., 2020;
Yao et al., 2020

Clinical Trial:
36 COVID-19 patients were administered
orally with hydroxychloroquine sulfate 200 mg
3 times daily for 10 days. The results showed
that 25 of 36 patients (about 70%) experienced
virological recovery
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Table 1. continued
Drug

Original Use

Azithromycin

Antibiotic

Corticosteroid
Antiinflammatory
(Dexamethasone)

E-ISSN 2477-0612

Anti-COVID-19
Mechanism
Azithromycin
regulates inflammatory
responses by increasing
immunoglobulin
production
and
suppressing
the
production
of
cytokines such as
TNF-α, IL-6, and IL8, so that the cytokine
storm reactions can be
avoided
Corticosteroid
can
suppress the proinflammatory cytokine
production, so the
cytokine storm reaction
could be avoided

Results

Development of Dosage Forms

In-vitro:
The EC50 value of azithromycin is 2.12 μM in
inhibiting the infection of SARS-CoV-2 to Vero
E6 cells.

Gautret et al., 2020;
Pani et al., 2020;
Touret et al., 2020;
Zarogoulidis et al.,
2012

Clinical Trial:
500 mg azithromycin combined with 600 mg
hydroxychloroquine on the first day and after
that azithromycin 250 mg was used once
daily for 4 days. The result showed that the
combination group showed negative results
from PCR results on the fifth day
Clinical trial:
Dexamethasone was administered to COVID-19
patients either orally or intravenously at a dose
of 6 mg per day for 10 days. After 28 days,
evaluation of mortality rate was performed. The
result obtained indicates that dexamethasone
can reduce the mortality rate by 12.3% in
patients using invasive mechanical ventilation
devices and 4.2% in patients using oxygen alone

References

Dexamethasone-loaded leukosomes:
The
dexamethasone-loaded
leukosome was made by loading
the dexamethasone-cyclodextrin
complex into the leucocyte
vesicles made of DPPC:DOPC:
cholesterol (4:3:3) and mixed with
the J774 macrophage membrane.
The result of preclinical trial
on mice shows that compared
to
dexamethasone
alone,
dexamethasone-loaded leukosome
had better activity in suppressing
the production of all tested proinflammatory cytokines

Ahmed & Hassan,
2020; Horby et al.,
2020; Molinaro et al.,
2020;Ramamoorthy
et al., 2017
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Table 1. continued
Anti-COVID-19
Mechanism
Statins
inhibit
the production of
cytokines, especially
IL-6

Drug

Original Use

Statins

Anti-hyperlipidemia

Vitamin C

Antioxidant

Vitamin C regulates
of pro-inflammatory
cytokine production,
so that cytokine storms
reaction can be avoided

ACEi

Antihypertension

ACEi inhibits the virus
to bind to the ACE2
receptor,
therefore
the infection can be
avoided

Results
Meta analysis:
There is a reduction in fatal or severe disease
by 30% with the use of statins in COVID-19
patients

Development of Dosage Forms

References
Sirtori,
2014;
Dashti-Khavidaki
& Khalili, 2020;
Troeman et al., 2013;
Kow & Hasan, 2020

De Melo & HomemDe-Mello, 2020

Clinical trial:
12,549 patients were tested for COVID-19 in
New York, 5,894 (46.8%) from these patients
were found positive, 1,002 (17%) from
these patients had severe illness. A history
of hypertension was present in 4,357 patients
(34.6%), among them 2,573 (59.1%) had
positive test results, and the remaining patients
had severe illness of COVID-19. There was no
association between ACEi or ARB medication
and there is no increased likelihood of positive
results

Lu et al., 2020;
Reynolds et al.,
2020
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Table 1. continued
Drug

Original Use

Colchicine

Antiinflammatory

Nitazoxanide

Antiparasitic

E-ISSN 2477-0612

Anti-COVID-19
Mechanism
Colchicine suppresses
the
caspase-1
activation and also
inhibits the production
of
inflammatory
cytokines, such as IL1β and IL-18
Nitazoxanide inhibits
the expression of
the viral N protein
and
potentiates
the production of
interferon-α
and
interferon-β

Results

Development of Dosage Forms

References

4,488 patients were administered orally with
colchicine 0.5 mg twice daily for the first 3
days and subsequently once daily for 27 days.
The result showed that even though it is not
significant but there was a reduction in mortality
rate about 0.1%

Schlesinger et al.,
2020;Gendelman
et al., 2020; Parramedina et al., 2020;
Tardif et al., 2021

In-vitro:
Nitazoxanide could inhibit SARS-CoV-2 virus
in Vero E6 cells with EC50 concentration of 2.12
μM

Mahmoud et al.,
2020; Cao et al.,
2020;
Rossignol,
2016; Wang et al.,
2020

Drug Repurposing and Dosage Form Development of Anti-COVID-19

of cholesterol in blood and also used to prevent
cardiovascular diseases (Sirtori, 2014). Besides their
role as inhibitors to prevent any cardiovacular disease,
statins are also reported to have a role in modulating
the immune response against COVID-19. Through
several studies, statins have been shown to decrease
inflammation, decrease the production of cytokines,
especially IL-6, and decrease lung injury (DashtiKhavidaki & Khalili, 2020; Troeman et al., 2013). A
study about anti-COVID-19 activity of several statins has
been performed in-silico, and the results showed that the
binding affinities of pitavastatin, rosuvastatin, lovastatin,
and fluvastatin with main protease of SARS-CoV-2 virus
(PDB ID: 6LU7) are -8.2, -7.7, -7.4, and 7.7 kcal/mol,
respectively. Therefore, it can be indicated that statins
could be efficient SARS-CoV-2 Mpro inhibitors (Reiner
et al., 2020). A meta-analysis from four studies about the
effect of statins in patient with COVID-19 also suggested
a reduction in fatal or severe disease by 30% with the use
of statins in COVID-19 patients (Kow & Hasan, 2020).
From these studies, it can be concluded that statins can
be a complementary therapy for COVID-19.
Vitamin C
Vitamin C is a water-soluble vitamin and is known
to have excellent antioxidant properties. Besides its
antioxidant abilities, vitamin C also plays a role in
regulating the immune system and is also able to provide
protection against viral infections, including SARSCoV-2 virus (Junaid et al., 2020). Therefore, vitamin
C has the potential to be one of the anti-COVID-19
therapies. A possible anti-COVID-19 mechanism of
vitamin C is through regulation of pro-inflammatory
cytokine production, so that cytokine storms reaction
can be avoided (De Melo & Homem-De-Mello, 2020).
However, informations regarding the effectiveness of
vitamin C as an anti-COVID-19 through in-vitro study,
in-vivo study and clinical trials are still not available,
therefore further research is still required.
Angiotensin Converting Enzyme Inhibitors (ACEi)
ACE2 is an enzyme responsible in converting angiotensin
I into angiotensin II in lungs. ACE2 receptors are the
entry point for SARS-CoV-2 virus to infect humans. If
the receptors were bound with ACEi drugs, the virus will
not be able to bind with the receptor anymore and the
infection might be avoided. ACEi was originally used
as antihypertension (Lu et al., 2020). An observational
study analyzed 12,549 patients who were tested for
COVID-19 in New York, with 5,894 (46.8%) patients
were found positive and 1,002 (17%) patients had
severe illness. A history of hypertension was present in
4,357 patients (34.6%), among them 2,573 (59.1%) had
positive test results, while others had severe illness of
COVID-19. There was no association between ACEi or
ARB medication and there is no increased likelihood of
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positive COVID-19 tests (Reynolds et al., 2020). A metaanalysis about the association of treatment with ACEi
or ARB and risk of severe/lethal COVID-19 strongly
suggests and supports the recommendation to continue
ARB or ACEi for all patients, unless otherwise advised
by their physicians who should thus be reassured (Flacco
et al., 2020).
Colchicine
Colchicine is an alkaloid compound and initially
was isolated from meadow saffron (Colchicum
autumnale). Colchicine has been commonly used as
antiinflammatory for gout treatment (Schlesinger et
al., 2020). This antiinflammatory effect is exhibited by
suppressing caspase-1 activation and also by inhibiting
the production of inflammatory cytokines, such as IL1β and IL-18 (Gendelman et al., 2020; Parra-medina et
al., 2020). Through this mechanism, colchicine might
play an important role in preventing the cytokine storm.
A retrospective study on 14,520 COVID-19 patients
in Israel found no significant difference in mortality
rate of colchicine use between patients with positive
and negative RT-PCR results for SARS-CoV-2, which
is 0.53% versus 0.48%. These results suggest that
colchicine might not have a protective role against
SARS-CoV-2 virus’ infection (Gendelman et al., 2020).
However, a clinical trial aimed to investigate the ability
of colchicine in reducing mortality rate of unhospitalized
COVID-19 patients has been performed on 4,488
patients by administering them orally with colchicine
0.5 mg twice daily for the first 3 days and subsequently
once daily for 27 days after. The result showed that even
though it is not significant but there was a reduction in
mortality rate about 0.1% (Tardif et al., 2021). In order
to have a certainty about colchicine activity against
COVID-19, further research is required.
Nitazoxanide
Nitazoxanide was approved by FDA as an antiparasitic
drug for diarrhea and enteritis triggered by
Cryptosporidium spp. since 2002 (Mahmoud et al., 2020).
Through in-vitro studies, it was known that nitazoxanide
also has an antiviral activity against coronavirus by
inhibiting the expression of the viral N protein, which
is the nucleocapsid of the virus, and nitazoxanide is
also known to potentiate the production of interferon-α
and interferon-β (Cao et al., 2020; Rossignol, 2016).
It has been hypothesized that nitazoxanide also has
similar mechanism against SARS-CoV-Virus. Wang
et al. (2020) have reported that nitazoxanide could
inhibit SARS-CoV-2 virus in Vero E6 cells with EC50
concentration of 2.12 μM. A clinical trial suggested that
using the combination of nitazoxanide and azithromycin
as a protocol for early stage of COVID-19 infection
might be safer and more effective than the combination
of hydroxychloroquine and azithromycin, although
E-ISSN 2477-0612
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further research to ensure this suggestion is still required
(Kelleni, 2020).
NEW DEVELOPMENT OF DOSAGE FORMS OF
ANTI-COVID-19 DRUGS
During this pandemic, many studies on drug repurposing
have been carried out. However, one of the biggest
obstacles in the treatment or therapy of COVID-19
today is the lack of effectiveness and safety of the drugs,
including the adverse effects that can occur during
therapy (Cavalcanti & Cajubá de Britto Lira Nogueira,
2020). Therefore, it is necessary to develop drugs that are
known to have potential and activity as anti-COVID-19
through drug repurposing so that the treatment or
therapy can be more effective and the drug’s adverse
effects can be minimized. Here are some examples of
anti-COVID-19 drugs that have been developed:
Dry Powder Inhalation Remdesivir
Sahakijpijarn et al. (2020) have conducted research to
develop remdesivir into a dry powder for inhalation
dosage form. Based on a previous clinical study of
remdesivir, it was found that 32 of 36 subjects (60%) who
received remdesivir intravenously had at least one side
effect and 12 subjects (23%) had a serious side effect.
The side effects include diarrhea, organ dysfunction
syndrome (septic shock), acute kidney damage, and
hypotension (Grein et al., 2020). Therefore, remdesivir
was developed into a dry powder for inhalation dosage
form, because the inhalation route of drug delivery can
provide several benefits, such as avoiding first-pass
metabolism of drugs, increasing the potential of drugs
locally in the lungs, and reducing the systemic drug side
effects. The method used in formulating the dry powder
dosage form was thin film freezing, which involves
freezing on the mixed solution and turning it into a
thin film layer, followed by lyophilizing it to produce
a dry powder. The evaluation results of the dry powder
indicated that the dosage form using leucine as their
excipient had satisfying aerodynamic characteristics
as indicated by 89 – 92% of the particle fractions that
were successfully sprayed (Sahakijpijarn et al., 2020).
However, information regarding the effectiveness and
safety of the developed remdesivir into dry powder for
in-vivo studies and clinical trials are still not available,
making it necessary to test the effectiveness of this
developed dosage form so that the efficacy and safety of
this dosage form could be more assured.
Dexamethasone-Loaded Leukosomes
Molinaro et al. (2020) have also developed dexamethasone
into nanoparticles called leukosomes. Leukosome is
a nanovesicle that is developed with characteristics
resembling leukocytes, so that the cleaning by the
mononuclear phagocytic system can be avoided and
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the drug delivery system can be modified to be targeted
delivery system. The dexamethasone-loaded leukosome
was formulated by loading the dexamethasonecyclodextrin complex into the leucocyte vesicles
made of dipalmitoylphosphatidylcholine (DPPC),
dioleoylphosphatidylcholine (DOPC) and cholesterol in
a ratio of 4:3:3 and mixed with the J774 macrophage
membrane. The dexamethasone-loaded leukosome
obtained has an average particle size of 120 nm with a
polydispersity index below 0.1, a zeta potential of -14 mV
and 75% of the dexamethasone loaded in the leukosome.
Based on the drug release test, it was shown that 75%
dexamethasone was released from the leukosome
system within 10 hours and reached 100% at 48 hours
in phosphate buffer medium (PBS) at 37 ̊C. Afterwards,
the activity on suppressing the pro-inflammatory
cytokines production of dexamethasone leukosome
was tested, including TNF-α, IL-1α, IL-6, macrophage
colony stimulating factor (M-CSF), circulating adhesion
molecule-1 (ICAM-1), monocyte, chemotactic protein-1
(MCP1), B lymphocyte chemoattractant (BLC),
CCL5 and complement components. Compared to
dexamethasone, dexamethasone-loaded leukosome had
better activity in suppressing the production of all tested
pro-inflammatory cytokines (Molinaro et al., 2020),
therefore dexamethasone-loaded leukosome can be
one of the anti-COVID-19 drug candidates that can be
developed and studied further.
Liposomal Hydroxychloroquine
Another study also conducts a development of
hydroxychloroquine by loading it into liposomes.
The reason for this development was due to the side
effects caused by hydroxychloroquine, which were
prolongation of the QT interval on heart rhythm and
hydroxychloroquine is also cardiotoxic at high doses.
Therefore, a liposome containing hydroxychloroquine
was developed and delivered via inhalation route to avoid
cardiotoxic and other systemic side effects. Liposome
vesicles were made using dipalmitoilphosphatidylcholine
(DPPC) and cholesterol. Based on in-vivo
pharmacokinetic studies in mice, it was found that in
the lung organs, inhaled hydroxychloroquine liposomes
had maximum concentration, area under the curve and
t1/2 were greater than intravenous hydroxychloroquine
and inhaled hydroxychloroquine. This indicates that
the hydroxychloroquine loaded in the liposomes has
an increasing ability to penetrate the lung tissue with
extended residence time. Meanwhile, when viewed in
different organs, the maximum concentration profile
and area under the curve of the hydroxychloroquine
liposomes in blood plasma and in the heart tissue are
lower than in lung tissue. This indicates that the delivery
of hydroxychloroquine liposomes via the inhalation
route has a local effect in the lung tissue (Tai et al.,
2020). However, information regarding clinical trials of
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inhaled liposomal hydroxychloroquine dosage form is
still not available. Therefore, it is still necessary to carry
out further research into the clinical trial stage so that the
efficacy and safety of the dosage form can be assured.
CONCLUSIONS
The development of anti-COVID-19 drugs was currently
performed through drug repurposing approach and
pharmaceutical dosage forms development. However,
the testing carried out on most of the newly developed
drugs and pharmaceutical dosage forms were still
limited to in-vitro and preclinical tests. Therefore, it is
still necessary to carry out further testing even to the
clinical testing stage so that the efficacy and the safety of
the drugs can be assured.
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